Cytek Biosciences, Inc. CTKB
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- +21.39%
- 1 year
- +60.47%
- Open
- 6.26
- Prev close
- 6.30
- Mkt cap
- 796.80M
- Vol
- 1.87M
- Avg vol
- 1.19M
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.05
- High
- 6.28
- Forward P/E
- 107.67
- Beta
- 1.32
- Short ratio
- 4.50
- Inst. own
- 59.02%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 6.03
- 200-d avg
- 5.92
- 1y target
- 8.40
2Y chart
Events in this range
- Nov 5, 2024Earnings: 0.01; estimate -0.02; surprise 150%
- Nov 11, 2024Rating: Piper Sandler · Overweight → Overweight
Signals (105)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 29, 2026 | 2 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Overbought | Oct 2, 2026 | 4 weeks ago |
| RSI: Overbought | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 21, 2026 | 3 months ago |
| SMA: Bullish | Jul 14, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 18, 2026 | 4 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| RSI: Oversold | May 13, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | May 11, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 2, 2026 | 7 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| SMA: Bullish | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 17, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 17, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| SMA: Bearish | Mar 11, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| RSI: Oversold | Feb 17, 2026 | 8 months ago |
| RSI: Oversold | Feb 12, 2026 | 8 months ago |
| RSI: Oversold | Feb 10, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 21, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| RSI: Overbought | Nov 21, 2025 | 11 months ago |
| RSI: Overbought | Nov 18, 2025 | 11 months ago |
| RSI: Overbought | Nov 14, 2025 | 11 months ago |
| RSI: Overbought | Nov 10, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 6, 2025 | 11 months ago |
| SMA: Bullish | Nov 5, 2025 | 12 months ago |
| SMA: Bullish | Nov 5, 2025 | 12 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Oct 30, 2025 | 1 year ago |
| SMA: Bearish | Oct 30, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 30, 2025 | 1 year ago |
| SMA: Bullish | Oct 21, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 8, 2025 | 1 year ago |
| SMA: Bearish | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Oct 3, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 3, 2025 | 1 year ago |
| SMA: Bearish | Sep 23, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 19, 2025 | 1 year ago |
| SMA: Bullish | Sep 11, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 22, 2025 | 1 year ago |
| SMA: Bearish | Jul 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jun 25, 2025 | 1 year ago |
| SMA: Bearish | Jun 13, 2025 | 1 year ago |
| SMA: Bullish | Jun 6, 2025 | 1 year ago |
| MACD: Buy Signal | May 30, 2025 | 1 year ago |
| RSI: Oversold | May 13, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| RSI: Oversold | May 9, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 7, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| RSI: Oversold | Mar 11, 2025 | 1 year ago |
| RSI: Oversold | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 27, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 18, 2025 | 1 year ago |
| SMA: Bearish | Jan 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
Key statistics
- Market cap
- 832.12M
- Enterprise value
- 550.82M
- Trailing P/E
- 0.00
- Forward P/E
- 107.67
- PEG ratio
- 0.00
- Price / sales
- 4.14
- Price / book
- 2.18
- EPS (TTM)
- -0.08
- Beta
- 1.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -5.05%
- Revenue (TTM)
- 201.21M
- Revenue growth
- 7.30%
- Free cash flow
- 40.66M
- Total cash
- 277.78M
- Total debt
- 14.52M
- Return on equity
- -2.54%
- Shares outstanding
- 128.81M
- Short % of float
- 3.95%
- 50-day average
- 6.03
- 200-day average
- 5.92
Analyst view
Consensus: buy
- Target (low)
- 7.00
- Target (mean)
- 8.40
- Target (high)
- 9.00
- Strong buy2
- Buy2
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate 0.11333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.02 | 0.01 | +0.03 | +150.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.03 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.03 | -0.08 | -0.05 | -166.67% |
| May 8, 2024 | Mar 1, 2024 | -0.05 | -0.05 | 0.00 | 0.00% |
| May 8, 2024 | Mar 1, 2024 | -0.05 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | 0.02 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | Piper Sandler | main | Overweight | Overweight |
| Aug 13, 2024 | Piper Sandler | main | Overweight | Overweight |
| May 13, 2024 | Piper Sandler | main | Overweight | Overweight |
| Mar 6, 2024 | Piper Sandler | main | Overweight | Overweight |
| Feb 29, 2024 | Goldman Sachs | main | Buy | Buy |
| Dec 14, 2023 | Stephens & Co. | init | — | Overweight |
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- cytekbio.com
News
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
- Cytek Biosciences Says Jury Finds In Cytek’s Favor On Three Of Four Asserted Patent Claims; To Challenge Remaining Finding; Jury Awarded Past Damages Consisting Of $20M In Lost Profits And $36M In Royalties
- Cytek Biosciences Q2 EPS $(0.09), Inline, Sales $48.140M Miss $48.610M Estimate
- Cytek Biosciences Raises FY2026 Sales Guidance from $205.000M-$212.000M to $207.000M-$212.000M vs $208.767M Est
- Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
- Concrete Pumping Holdings Reports Blowout Q2 Results, Joins ServiceTitan and Other Big Stocks Moving Higher in Friday's Pre-Market Session
- Braze Posts Mixed Q1 Results, Joins Sidus Space, Everpure And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- Why Phreesia Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
- Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75
Your note
Sign in to keep a note on CTKB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNETT VALERIE | Officer | Conversion of Exercise of derivative security | Nov 17, 2024 | 62,850 |
| BUSQUE PHILIPPE | Officer | Conversion of Exercise of derivative security | Nov 17, 2024 | 12,871 |
| GARLAND JONATHAN TODD | Officer | Conversion of Exercise of derivative security | Aug 17, 2023 | 8,763 |
| HOLDER MICHAEL | Director | Conversion of Exercise of derivative security | Nov 17, 2024 | 3,635 |
| JEANMONOD PATRIK | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 10, 2024 | 97,465 |
| JIANG WENBIN | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 17, 2024 | 5,187,640 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.36% | 18,492,291 | 119.46M | Sep 29, 2024 |
| Vanguard Group Inc | 9.14% | 11,778,054 | 76.09M | Sep 29, 2024 |
| Brown Capital Management, LLC | 7.37% | 9,493,474 | 61.33M | Sep 29, 2024 |
| HHLR Advisors, LTD | 5.17% | 6,657,030 | 43.00M | Sep 29, 2024 |
| State Street Corporation | 3.24% | 4,167,501 | 26.92M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.07% | 2,668,004 | 17.24M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 5.29% | 6,819,167 | 44.05M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.70% | 3,474,084 | 22.44M | Sep 29, 2024 |
| Brown Capital Management Small Company Fund | 2.69% | 3,464,590 | 22.38M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.42% | 3,121,619 | 20.17M | Oct 30, 2024 |
| Vanguard Small-Cap Index Fund | 2.05% | 2,637,310 | 17.04M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.20% | 1,542,181 | 9.96M | Sep 29, 2024 |